Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.

Trial Details

NCT ID

NCT07140679

Phase

PHASE2

Sponsor

Emory University

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Biopsy Procedure
Biospecimen Collection
Colonoscopy
Computed Tomography
Questionnaire Administration
Toripalimab

Locations (sample)

Atlanta, Georgia, United States|33.749,-84.38798
Atlanta, Georgia, United States|33.749,-84.38798
Atlanta, Georgia, United States|33.749,-84.38798
Atlanta, Georgia, United States|33.749,-84.38798
Johns Creek, Georgia, United States|34.02893,-84.19858

Key Eligibility Criteria

Patients with resected pathologic stage IIB, IIC and III dMMR colon cancer (American Joint Committee on Cancer \[AJCC\] 8)
Deficient mismatch repair (MMR) by immunohistochemistry or microsatellite instability (MSI-H) by polymerase chain reaction (PCR) or next generation…
Complete (R0) resection of pathologic stage IIB, IIC and III dMMR colon cancer 4 to 12 weeks prior to first dose of study drug
Available tissue sample from surgical specimen

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →